Health related quality of life after combined hormone replacement therapy: randomised controlled trial
- PMID: 18719013
- PMCID: PMC2518695
- DOI: 10.1136/bmj.a1190
Health related quality of life after combined hormone replacement therapy: randomised controlled trial
Abstract
Objective: To assess the effect of combined hormone replacement therapy (HRT) on health related quality of life.
Design: Randomised placebo controlled double blind trial.
Setting: General practices in United Kingdom (384), Australia (94), and New Zealand (24).
Participants: Postmenopausal women aged 50-69 at randomisation; 3721 women with a uterus were randomised to combined oestrogen and progestogen (n=1862) or placebo (n=1859). Data on health related quality of life at one year were available from 1043 and 1087 women, respectively.
Interventions: Conjugated equine oestrogen 0.625 mg plus medroxyprogesterone acetate 2.5/5.0 mg or matched placebo orally daily for one year.
Main outcome measures: Health related quality of life and psychological wellbeing as measured by the women's health questionnaire. Changes in emotional and physical menopausal symptoms as measured by a symptoms questionnaire and depression by the Centre for Epidemiological Studies depression scale (CES-D). Overall health related quality of life and overall quality of life as measured by the European quality of life instrument (EuroQol) and visual analogue scale, respectively.
Results: After one year small but significant improvements were observed in three of nine components of the women's health questionnaire for those taking combined HRT compared with those taking placebo: vasomotor symptoms (P<0.001), sexual functioning (P<0.001), and sleep problems (P<0.001). Significantly fewer women in the combined HRT group reported hot flushes (P<0.001), night sweats (P<0.001), aching joints and muscles (P=0.001), insomnia (P<0.001), and vaginal dryness (P<0.001) than in the placebo group, but greater proportions reported breast tenderness (P<0.001) or vaginal discharge (P<0.001). Hot flushes were experienced in the combined HRT and placebo groups by 30% and 29% at trial entry and 9% and 25% at one year, respectively. No significant differences in other menopausal symptoms, depression, or overall quality of life were observed at one year.
Conclusions: Combined HRT started many years after the menopause can improve health related quality of life.
Trial registration: ISRCTN 63718836.
Conflict of interest statement
Competing interests: AHM has received research grants and lecture honoraria from various pharmaceutical companies but not in association with this study. BAL has received research and travel grants and lecture honoraria from various pharmaceutical companies but not in association with this study.
Comment in
-
Hormone replacement therapy: Irresponsible to modify current guidelines.BMJ. 2008 Sep 3;337:a1494. doi: 10.1136/bmj.a1494. BMJ. 2008. PMID: 18768558 No abstract available.
-
Patient reported outcome measures in trials.BMJ. 2009 Jan 12;338:a2597. doi: 10.1136/bmj.a2597. BMJ. 2009. PMID: 19139137 No abstract available.
-
Does combined hormone replacement therapy improve the health-related quality of life of postmenopausal women?Nat Clin Pract Endocrinol Metab. 2009 Mar;5(3):136-7. doi: 10.1038/ncpendmet1079. Nat Clin Pract Endocrinol Metab. 2009. PMID: 19229231
Similar articles
-
Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73. doi: 10.1097/01.AOG.0000158120.47542.18. Obstet Gynecol. 2005. PMID: 15863546 Clinical Trial.
-
Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women.BMJ. 2007 Aug 4;335(7613):239. doi: 10.1136/bmj.39266.425069.AD. Epub 2007 Jul 11. BMJ. 2007. PMID: 17626056 Free PMC article. Clinical Trial.
-
The effect of Chinese herbal medicines (CHM) on menopausal symptoms compared to hormone replacement therapy (HRT) and placebo.Maturitas. 2007 Sep 20;58(1):83-90. doi: 10.1016/j.maturitas.2007.06.005. Epub 2007 Aug 8. Maturitas. 2007. PMID: 17689896 Clinical Trial.
-
The Women's Health Initiative Randomized Trials and Clinical Practice: A Review.JAMA. 2024 May 28;331(20):1748-1760. doi: 10.1001/jama.2024.6542. JAMA. 2024. PMID: 38691368 Review.
-
Hormone replacement therapy after surgery for epithelial ovarian cancer.Cochrane Database Syst Rev. 2020 Jan 28;1(1):CD012559. doi: 10.1002/14651858.CD012559.pub2. Cochrane Database Syst Rev. 2020. PMID: 31989588 Free PMC article.
Cited by
-
Insomnia in Postmenopausal Women: How to Approach and Treat It?J Clin Med. 2024 Jan 12;13(2):428. doi: 10.3390/jcm13020428. J Clin Med. 2024. PMID: 38256562 Free PMC article. Review.
-
Effect of Soy Milk Consumption on Quality of Life in Iranian Postmenopausal Women.J Family Reprod Health. 2015 Jun;9(2):93-100. J Family Reprod Health. 2015. PMID: 26175764 Free PMC article.
-
Postmenopausal hormone therapy: an Endocrine Society scientific statement.J Clin Endocrinol Metab. 2010 Jul;95(7 Suppl 1):s1-s66. doi: 10.1210/jc.2009-2509. Epub 2010 Jun 21. J Clin Endocrinol Metab. 2010. PMID: 20566620 Free PMC article. Review.
-
Sex-dependent mental illnesses and mitochondria.Schizophr Res. 2017 Sep;187:38-46. doi: 10.1016/j.schres.2017.02.025. Epub 2017 Mar 6. Schizophr Res. 2017. PMID: 28279571 Free PMC article. Review.
-
Does combined hormone replacement therapy improve the health-related quality of life of postmenopausal women?Nat Clin Pract Endocrinol Metab. 2009 Mar;5(3):136-7. doi: 10.1038/ncpendmet1079. Nat Clin Pract Endocrinol Metab. 2009. PMID: 19229231
References
-
- Testa MA, Nackley JF. Methods for quality of life studies. Annu Rev Public Health 1994;15:535-59. - PubMed
-
- Cella DF. Methods and problems in measuring quality of life. Support Care Cancer 1995;3:11-22. - PubMed
-
- Limouzin-Lamothe MA, Mairon N, Joyce CR, Le Gal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170:618-24. - PubMed
-
- Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002;288:321-33. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical